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1. Introduction {#sec0005}
===============

During the coronavirus disease 2019 (COVID-19) pandemic, international efforts have been made to inform and prepare health care workers in order to optimize and redirect resources and personnel to manage this crisis. As of May 4, 2020, the World Health Organization (WHO) reported 239 604 deaths [@bib0005]. To date, there is no approved vaccine for COVID-19, and the number of cases has continued to rise as of the date of submission.

Several urology societies and reference centers have published recommendations to inform urology care during the COVID-19 pandemic.

It is essential for urologists to prioritize patient safety, and to balance potential delays in diagnosis and treatment of urological conditions against risks of COVID-19 exposure and additional stress on health care resources. These issues are of particular concern in epicenters or areas with the greatest number of cases.

The aim of this systematic review is to summarize published guidelines and recommendations on urological care during the COVID-19 pandemic from major professional urology societies and reference centers.

2. Evidence acquisition {#sec0010}
=======================

2.1. Search strategy {#sec0015}
--------------------

A comprehensive literature search was performed using a combination of keywords (MeSH terms and free text words) including ("COVID-19" OR "SARS-CoV-2" OR "Coronavirus" OR "coronavirus infections") AND ("Urology" OR "Urogenital system"). MEDLINE, EMBASE, and CINAHL were searched (Supplementary material). The search was supplemented to include references from the pertinent articles as well as hand searches of additional relevant records on COVID-19 resource websites from the European Association of Urology (EAU), American Urological Association (AUA), and *British Journal of Urology International*. Our search was up-to-dated to include publications through April 17, 2020.

2.2. Eligibility criteria {#sec0020}
-------------------------

Articles were eligible for inclusion if they contained original guidelines or recommendations on urology standards of care during the COVID-19 pandemic.

2.3. Information sources {#sec0025}
------------------------

Our search strategy yielded 366 articles. All the articles were combined into EndNote reference management software, and 127 duplicates were removed. Two authors (M.L.W. and F.L.H.) independently identified and reviewed the titles and abstracts. For an article to be excluded, both reviewers had to agree that the study was not relevant. The exclusion criteria were as follows: (1) not focused on urology, (2) not containing recommendations involving urology practice during COVID-19, and (3) not written in English. After reviewing the titles and abstracts, 72 papers were identified as potentially eligible for inclusion. After a full-text review, 15 were deemed eligible and were included. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram is shown in [Fig. 1](#fig0005){ref-type="fig"} .Fig. 1PRISMA flowchart summarizing the results of the literature search. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses.Fig. 1

2.4. Data extraction {#sec0030}
--------------------

Two independent reviewers (F.S.L. and F.L.H.) extracted all relevant recommendations from each guideline. Disagreements concerning data extraction were resolved by discussion and consensus. Thereafter, a recommendation matrix was constructed considering distinct conditions, such as urological oncology, endourology, outpatient procedures, other benign procedures, emergencies, and transplantation. The following variables were extracted from the articles: list of authors, title of the article, publication date, country, search strategy, purpose of the guideline, guideline type, subareas covered, and conclusions.

3. Evidence synthesis {#sec0035}
=====================

For quality assessment, the team checked for the level of evidence and grade of recommendations.

The authors summarized the recommendations using a triage grading system based on two factors: (1) possible impairment in patient condition or survivorship if surgery is not performed and (2) different regional health care resource settings ([Fig. 2](#fig0010){ref-type="fig"} ).Fig. 2Proposed emergency and elective procedures triage color codes to summarize collated evidence, integrating survival and healthcare resources.Fig. 2

Published data were used for this systematic review; hence, no ethical approval was sought.

4. Results {#sec0040}
==========

4.1. Study selection and characteristics of the included guidelines {#sec0045}
-------------------------------------------------------------------

All 15 included articles were accepted for publication between March 15 and April 17, 2020. The articles came from various institutions in Europe (Italy, UK, Belgium, and Switzerland), the Americas (USA, Canada, and Brazil), and Australia/New Zealand. All the 15 guidelines were based on expert opinion ([Table 1](#tbl0005){ref-type="table"} ).Table 1List of included articles.Table 1Author(s)/title/journalDate\
Month, day (2020)Situation reportedObjectiveSubareasMethodsTopicsGlobal\
Total confirmed cases/total deathsCountry\
Total confirmed cases\
Total deaths (new deaths in 24 h)Ficarra et al [@bib0010]/Urology practice during COVID-19 pandemic/Minerva Urol NefrolMarch 23332 930/14 50959 138 cases\
5476 (649) deaths\
ItalyTo summarize the procedures that should be performed in urgent, nonurgent, postponed conditions for the corresponding urological disorderUro-oncology, endourology, outpatients, benign conditions, emergenciesExpert opinionUrgencies, bladder, prostate, testicular, penile, cystoscopyStensland et al [@bib0065]/Considerations in the triage of urologic surgeries during the COVID-19 pandemic/Eur UrolMarch 25413 467/18 43369 176 cases\
6820 (743) deaths\
Italy\
8081 cases\
422 (87) deaths\
UKTo recommend surgeries and rationality to delay or treatUro-oncology, endourology, outpatients, benign conditions, emergenciesExpert opinionGeneralMottrie et al [@bib0050]/ERUS (EAU Robotic Urology Section) guidelines during COVID-19 emergency/Eur UrolMarch 25413 467/18 433220 516 cases\
11 986 (1797) deaths\
EuropeRecommendations, based on the most recent scientific pieces of evidence, to safeguard the health of health care workers and their patients, in the context of robotic surgeryUro-oncology (robotics)GuidelinesUrothelial cancer, prostate, renal mass, testicular, functional, reconstructiveUSANZ [@bib0015]/Guidelines for urological prioritisation during COVID-19March 25413 467/18 4332252 Cases\
8 (1) deaths\
Australia\
189 cases\
0 (0) death\
New ZealandGuidelines for surgical prioritizationUro-oncology, endourology, outpatients, benign conditions, emergenciesSociety guidelinesUro-oncology, urgencies, endourology, outpatientsKatz et al [@bib0040]/Triaging office-based urology procedures during the COVID-19 pandemic/J UrolMarch 25413 467/18 43351 914 cases\
673 (202) deaths\
USARepresenting a collection of urologists from several institutions across 45 countries, with expertise in different subspecialty fields of urology---seek to provide 46 frameworks to help triage office-based proceduresUro-oncology, endourology, outpatients, benign conditions, emergenciesExpert opinionCystoscopy, prostate biopsies, ureteral stent removal, urodynamics, female urologyKutikov et al [@bib0030]\
/A war on two fronts: cancer care in the time of COVID-19/Ann Intern MedMarch 27509 164/23 33568 334 cases\
991 (107) deaths\
USAGuidance on decisions about immediate cancer treatmentUro-oncologyExpert opinionUrothelial cancer, prostate, renal mass, testicularGoldman and Haber [@bib0020]/Recommendations for tiered stratification of urologic surgery urgency in the COVID-19 era/J UrolMarch 30693 282/33 106122 653 cases\
2112 (444) deaths\
USARecommended surgical priority tiersUro-oncology, endourology, outpatients, benign conditions, emergenciesExpert opinionDiagnostic cystoscopy, surveillance cystoscopy, intravesical instillations for bladder cancer, prostate biopsies and administration of androgen deprivation, cystoscopy with ureteral stent removal, Foley and suprapubic catheter exchanges, urodynamicsAhmed et al [@bib0070]/Global challenges to urology practice during COVID-19 pandemic/BJU IntApril 3972 303/50 32138 700 cases\
2910 (389) deaths\
UKPutting together a collection of the latest BJUI-published articles on the topic.\
Adapted from RCS Intercollegiate General Surgery GuidanceUro-oncology, endourology, outpatients, benign conditions, emergenciesExpert opinionOutpatients, general safetyLalani et al [@bib0075]/Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic/Can Urol Assoc JApril 51 133 758/62 78412 938 Cases\
214 (62) deaths\
Canada18 academic genitourinary medical oncologists from 11 cancer centers across Canada participated in preparing this guidance document for managing patients during the current pandemicUro-oncologyExpert opinionUrothelial cancer, prostate, renal mass, testicularCarneiro et al [@bib0035]/Impact of the COVID-19 pandemic on the urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period/Int Braz J UrolApril 91 436 198/85 52113 717 cases\
667 (114) deaths\
BrazilProviding suggestions and recommendations for the management of urological conditions in times of COVID-19 crisis in Brazil and other low- and middle-income countriesUro-oncology, endourology, outpatients, benign conditions, emergenciesExpert opinionUrolithiasis, BPH, hematuria, urgencies, urodynamic, prostate biopsy, intravesical instillations, urothelial cancer, prostate, renal mass, testicularQuaedackers et al [@bib0080]/Clinical and surgical consequences of the COVID-19 pandemic for patients with pediatric urological problems: statement of the EAU Guidelines Panel for Paediatric Urology/J Pediatr UrolApril 91 436 198/85 521759 661 cases\
61 516 (3877) deaths\
EuropeStatement with recommendations for pediatric urological cases based on published studies as well as expert opinion of the pediatric urology guidelines panel of the EAUPediatric urologySociety guidelinesPediatric urologyProietti et al [@bib0085]/Endourological stone management in the era of the COVID-19/Eur UrolApril 141 844 863/117 021159 516 Cases\
20 465 (564) deaths\
ItalyPrioritization scheme for stone patients scheduled for surgery during the COVID-19 pandemicEndourologyExpert opinionUrolithiasisGillessen et al [@bib0090]/Advice regarding systemic therapy in patients with urological cancers during the COVID-19 pandemic/Eur UrolApril 172 074 529/139 37826 651 cases\
1016 (43) deaths\
Switzerland\
103 097 cases\
13 729 (861)\
UKProviding treatment guidelines as a pragmatic perspective on the risk/benefit ratioUro-oncologyExpert opinionUrothelial cancer, prostate, renal mass, testicularRibal et al [@bib0025]/EAU Guidelines Office-Rapid-Reaction-Group. An organization wide collaborative effort to adapt the EAU guidelines recommendations to the COVID-19 eraApril 172 074 529/139 3781 050 871 cases\
93 480 (4163) deaths\
EuropeTreatment guidelines with most levels of evidence using a 4-level priorityUro-oncology, endourology, outpatients, benign conditions, emergenciesSociety guidelinesUrothelial cancer, prostate, renal mass, testicularMetzler et al [@bib0045]/Stone care triage during COVID-19 at the University of Washington/J EndourolApril 172 074 529/139 378632 781 Cases\
28 221 (2350) deaths\
USACategorizing patients into five groups of priorityEndourologyExpert opinionUrolithiasis[^1]

4.2. Uro-oncology {#sec0050}
-----------------

Postponing treatments for low- and intermediary-risk prostate cancer (PCa) was widely proposed as it is unlikely to result in clinical harm. Concerning high-risk PCa, some authors disagree upon postponement of surgery, while the others recommended proceeding with radical prostatectomy [@bib0010], [@bib0015]. Goldman and Haber [@bib0020] stated that surgery can be delayed beyond 3 mo, and Ribal et al [@bib0025] and Kutikov et al [@bib0030] recommended treatment before the end of 3 mo. Indeed, considering the EAU guideline, depending on the local situation of the pandemic, surgery for high-risk PCa can be postponed until after the pandemic [@bib0025]. Prescribing neoadjuvant androgen deprivation therapy in this situation is an option [@bib0025], [@bib0030], [@bib0035]. In the case of muscle-invasive bladder cancer, several authors stated that radical cystectomy is nondeferrable and neoadjuvant chemotherapy can be omitted \[5,6,8,\]. Carneiro et al \[7\] suggested that neoadjuvant chemotherapy can be delayed for up to 6--8 wk and cystectomy can be delayed for up to 10 wk. The authors agreed that a delay of \<3 mo is acceptable for T1b-T2 renal tumors. Another concern is metastatic renal cell carcinoma. The EAU panel discussed that cytoreductive surgery is controversial irrespective of the pandemic [@bib0025]. Only two articles covered recommendations regarding adrenal masses, and both agreed that adrenal masses \>4 cm or functional should be treated in \<1 mo \[4,8\]. Orchiectomy for suspected testicular tumors is nondeferrable. While several authors suggested starting adjuvant radiotherapy or chemotherapy for stage I seminomas, the EAU guidelines recommended active surveillance as the first choice of management for stage I seminoma [@bib0025]. Finally, concerning penile cancer, due to the lack of objective response and immunodeficiency from chemotherapy, palliative treatments and supportive care are recommended for metastatic penile cancer during the pandemic [@bib0025]. The synthesis of recommendations for uro-oncology is provided in [Table 2](#tbl0010){ref-type="table"} .Table 2Summary of guidelines: urologic oncology during COVID-19 pandemic.Table 2Prostate cancerAge/recommendationSurgeryRadiationCancer riskLowIntermediateHighHigh riskMetastatic hormone sensitiveFicarra et al [@bib0010]NondeferrableStensland et al [@bib0065]Safe delay 12 moSafe delay 12 moIf patient is ineligible for radiationConsider radiation (for intermediary risk = safe delay 12 mo)Mottrie [@bib0050]To postponeHighMediumWeakUSANZ [@bib0015]Active surveillanceInitial ADT + deferred definitive treatmentAs plannedKatz et al [@bib0040]Delay 6-8 weeksKutikov et al [@bib0030]\<50 yrSafe delay \>3 moSafe delay \>3 moProceed w/ immediate treatment. Delay \<3 mo acceptableConsider starting androgen deprivation if significant delay50--70 yrBalance risk and benefits of immediate treatment\>70 yrConsider starting androgen deprivation if significant delayGoldman and Haber [@bib0020]Can be delayed beyond 12 wkAhmed et al [@bib0070]As plannedLalani et al [@bib0075]Can be delayed up to 6 moCarneiro et al [@bib0035]PostponeConsider starting androgen deprivationConsider starting androgen deprivationGillessen et al [@bib0090]Commence where possibleRibal et al [@bib0025]Postpone treatment for 6-12 mo\
Active surveillance defer by 6 moSurgery can be postponed until after pandemicTreat before end of 3 mo or can be postponed until after pandemic\
If patient anxious or N1, consider ADT + EBRT as alternativeTreat before end of 3 mo (use immediate neoadjuvant ADT up to 6 mo followed by EBRT)Offer immediate systemic treatment to M1\
If low volume and planned ADT + EBRT, postpone EBRT until pandemic is no longer a major threatSummary44321Age/recommendationBladder cancerUpper tract U cancerLow gradeRefractory CISSuspected \> cT1High-grade non--muscle invasiveMuscle invasiveMultimodality bladder sparingMetastatic first-line treatmentPresume low-risk (ureteroscopy or surgery)High-grade nephroureterectomyMetastatic first-line treatmentFicarra et al [@bib0010]NondeferrableNondeferrableNondeferrableNondeferrableStensland et al [@bib0065]Proceed w/ immediate treatmentProceed w/ immediate treatmentProceed w/ immediate treatment regardless of the receipt of neoadjuvant chemoProceed w/ immediate treatmentMottrie [@bib0050]To postponeMediumWeakWeakWeakMediumWeakUSANZ [@bib0015]As plannedAs plannedAs plannedAs plannedConsider neoadjuvant chemoKutikov et al [@bib0030]\<70 yrSafe delay \>3 moProceed w/ treatment. Delay \<3 mo acceptableProceed w/ treatment. Delay \<3 mo acceptable\>70 yrSafe delay \>3 moBalance risk and benefits of immediate treatmentBalance risk and benefits of immediate treatmentGoldman and Haber [@bib0020]Delayed 4--12 wkScheduleScheduleDelayed beyond 4-12 wkScheduleAhmed et al [@bib0070]PriorityPriorityLalani et al [@bib0075]As plannedAdjuvant delayAdjuvant delay whenever possibleCarneiro et al [@bib0035]DelayProceed w/ immediate treatmentProceed w/ immediate treatmentProceed w/ immediate treatmentNeoadjuvant chemo can be delayed for up to 6--8 wk, cystectomy delay for up 10 wkProceed w/ immediate treatmentGillessen et al [@bib0090]Commenced where possibleCommenced where possibleRibal et al [@bib0025]Defer by 6 moTreat before end of 3 moTreat within \<6 wkTreat within \<6 wkTreat before end of 3 mo (consider omitting neoadjuvant chemo in T2/T3)Treat before end of 3 mo\
If palliative (consider only radio + chemo)Treat within \<6 wk\
Chemo adjuvant for N+Not recommended to postpone \>3 moTreat within \<6 wkTreat before end of 3 moSummary4222222311Age/\
recommendationKidney cancerAdrenalSRM \<4 cmT1b-T2T3Metastatic intermediate and poor riskCA suspected/symptomaticCA not suspectedFicarra et al [@bib0010]Nondeferrable in selective casesNondeferrableStensland et al [@bib0065]Delay \<3 mo acceptable or other forms of ablative approachesDelay \<3 mo acceptableProceed w/ treatmentProceed w/ immediate treatmentGillessen et al [@bib0090]Commenced where possibleMottrie [@bib0050]To postponeMediumMediumWeakUSANZ [@bib0015]\>7 cm = as plannedAs plannedKutikov et al [@bib0030]\<50 yrSafe delay \>3 moProceed w/ immediate treatment. Delay \<3 mo acceptable50--70 yrSafe delay \>3 moproceed w/ immediate treatment. Delay \<3 mo acceptable\>70 yrSafe delay \>3 moBalance risk and benefits of immediate treatmentGoldman and Haber [@bib0020]Can be delayed beyond 12 wkCan be delayed 4--12 wkScheduledCan be delayed up to 4 wkCan be delayed beyond 12 wkAhmed et al [@bib0070]PriorityPriorityLalani et al [@bib0075]RecommendedCarneiro et al [@bib0035]DelayAvoid delayProceed w/ treatmentProceed w/ treatmentRibal et al [@bib0025]Defer by 6 moTreat before end of 3 moTreat within \<6 wkTreat within \<6 wk\
Consider starting on VEGFR TKI rather than immune checkpoint inhibitor therapy\
Cytoreductive for asymptomatic is controversial irrespective of the pandemicSummary432124Testicular cancerPenile cancerOrchiectomyPostchemo RPLNDMetastaticLocalMetastaticStage 1 seminomaStage ≥ IIB seminoma or NSGCTFicarra et al [@bib0010]NondeferrableNondeferrableNondeferrableStensland et al [@bib0065]Proceed w/ immediate treatmentFavor chemotherapy or radiationChemotherapy use should be balanced by concern for immunosuppressionProceed w/ immediate treatmentUSANZ [@bib0015]As plannedConsider deferral if suggestive of slowly growing mature teratomaKutikov et al [@bib0030]Proceed w/ immediate treatmentProceed w/ immediate treatmentGoldman and Haber [@bib0020]ScheduleCan be delayed up to 4 wkScheduleLalani et al [@bib0075]Minimum delay if possibleNot to initiate adjuvant chemotherapy(Stage II seminoma or good-risk GCT with COVID-19 diagnosis) discuss chemotherapy delay whenever possibleCarneiro et al [@bib0035]As soon as possibleRadiotherapy whenever possible (stage 2 low-volume seminoma)Gillessen et al [@bib0090]Curative intent commenced where possibleRibal et al [@bib0025]May be postponed 2--3 dTreat within \<6 wkActive surveillance is the first choice of managementTreat within \<24 hTreat within \<6 wkConsider palliation insteadSummary122024[^2]

4.3. Endourology {#sec0055}
----------------

Nine of the included guidelines (60%) contained recommendations related to endourology procedures. Obstructed or infected renal and ureteral stones should be considered emergencies, and decompression should be performed. However, there is a consensus that treatment of nonobstructed renal stones can be delayed for months. Nevertheless, it is important to note that patients with symptomatic ureteral/renal stone and those with pre-existing stent should be considered priorities. However, authors disagreed on the maximum waiting time ranging from 6--8 to 12 wk [@bib0020], [@bib0025], [@bib0045]. A comparison of endourology recommendations between guidelines is displayed in [Table 3](#tbl0015){ref-type="table"} .Table 3Summary of guidelines: endourology (urolithiasis) procedures during COVID-19 pandemic.Table 3Nonobstructing renal stoneNonobstructing ureteral stoneRenal colicStent removalStone with stent/nephrostomy tube or symptomaticObstructed kidney/infectionFicarra et al [@bib0010]Postpone up to 6 moEmergencyStensland et al [@bib0065]up to 6--12 moEmergencyEmergencyUSANZ [@bib0015]DelayDelayAs plannedAs plannedAs plannedKatz et al [@bib0040]Without delayConsider no delayGoldman and Haber [@bib0020]Can be delayed beyond 12 wkScheduleCan be delayed up to 4 wkCan be delayed 4--12 wkEmergencyAhmed et al [@bib0070]UrgentCarneiro et al [@bib0035]Managed clinicallyDelayNot to delayEmergencyProietti et al [@bib0085]DelayDelayManaged conservativelyDelayDelay but consider prioritiesNot to delay = only decompressionMetzler et al [@bib0045]Postpone\<2--4 wk\<2--4 w (if recurrent ED visits)\<4--8 wkEmergencyRibal et al [@bib0025]Clinical harm very unlikely if postponed \>6 moClinical harm possible if postponed 3--4 mo, but unlikelyPain relief\
Avoid NSAIDs (ibuprofen) when possibleClinical harm very unlikely if postponed \>6 mo (as soon situation allows)Clinical harm very likely if postponed \>6 wkUrgent decompression of the collecting system (PCN or stent)Summary444320[^3]

4.4. Laparoscopy and robotics {#sec0060}
-----------------------------

Five of the 15 guidelines (30%) included recommendations for laparoscopic/robotic surgeries ([Table 4](#tbl0020){ref-type="table"} ). Some recommendations were made about the surgical technique and surgical team, such as lower electrocautery power settings to generate less smoke that could potentially transport the virus. Moreover, urologists can consider using lower pressure on insufflation system with integrated active smoke evacuation mode. In addition, presence in the operating room should be restricted to essential staff and the operating room team must wear full personal protective equipment.Table 4Summary of guidelines: robotic procedures during COVID-19 pandemic.Table 4Operation techniquePneumoperitoneum disinflationSurgical techniqueMottrie [@bib0050]Lower electrocautery power settingUse of system with integrated active smoke evacuation modeMinimum number of OR staff members\
Fellows temporarily suspended\
Adopt adequate PPEAhmed et al [@bib0070]Safety undeterminedPositive pressurization offQuaedackers et al [@bib0080]Use suction devices as much as possibleKeep intraperitoneal pressure as low as possible and aspirate the inflated CO~2~Carneiro et al [@bib0035]Pressure as low as possible + use filterPositive pressurization off\
Adopt adequate PPERibal et al [@bib0025]Electrosurgery units to the lowest settings\
Avoid or reduce use of monopolar electrosurgery, ultrasonic dissectors, and advanced bipolarKeep intraperitoneal pressure as low as possible and aspirate the inflated CO2 as much as possible before removing the trocarsAll nonessential staff should stay outside\
Surfaces should be decontamination with chlorine (5000--10 000 mg/l; note that chlorhexidine is ineffective against COVID-19 and is not appropriate)[^4]

4.5. Outpatient procedures (urological oncology, neurourology, female urology, and pediatric urology) {#sec0065}
-----------------------------------------------------------------------------------------------------

Recommendations for ambulatory procedures are presented in [Table 5](#tbl0025){ref-type="table"} . Not all experts recommended cystoscopy for immediate investigation of macroscopic hematuria, and a delay of 1--2 mo was recommended [@bib0025]. Postponing prostate biopsy was not a consensus, and a case-by-case consideration should guide these decisions. Indeed, the Urological Society of Australia and New Zealand (USANZ) stated that Prostate Imaging Reporting and Data System (PIRADS) 4/5 should be managed as planned; EAU suggested that there should not be a delay of \>6 wk for symptomatic patients [@bib0015], [@bib0025]. Stage 2 neuromodulation should be carried on due to the possibility of infection. Authors disagreed on the timing of treating mesh complications and fistula repair. Most pediatric urology surgeries can be postponed, except for some oncological conditions or those that may lead to loss of renal function.Table 5Summary of guidelines: outpatient procedures during COVID-19 pandemic (urologic oncology, neurourology, female urology, and pediatric urology).Table 5Uro-oncologyNeurourologyFemale urologyPediatric urologyBladder CAProstate biopsyNeurogenic cysto/BotoxUrodynamicsStage 2 sacral neuromodulationUrethral diverticula/mesh removal/sling incision/fistulaSlings, pelvic organ prolapse, sacral, pessary cleaning/exchange neuromodulation stage 1, artificial urethral sphincterPediatric: pyeloplasty with severe symptoms, posterior urethral valves. obstructed megaureter with loss of function, urolithiasis with recurring febrile infectionsReimplant, penile and benign testicular cases and buried penis, living donor renal txSurveillance cystoscopyIntravesical BCG/chemotherapy induction or postoperativeIntravesical BCG/chemotherapy maintenanceLow or intermediate riskHigh riskLow or intermediate riskHigh riskLow or intermediate riskHigh riskFicarra et al [@bib0010]PostponeDo not postponePostponeStensland et al [@bib0065]Proceed w/ immediate treatmentDelayDelayMottrie [@bib0050]USANZ [@bib0015]PIRADS 4/5 = as plannedKatz et al [@bib0040]Safe delay 3--6 moProceed w/ immediate investigationPatients should be prioritized for treatmentDelay indefinitelyStop and re-evaluate in 3 moSafe delay 3 mo, suggest transperineal\
Safe delay 3--6 mo (if low or intermediate PCa suspected)Delay for 3--6 mo GU tract dysfunctionWithout delayDelay 3--6 moGoldman and Haber [@bib0020]PSA \>15 = can be delayed 4--12 wkNeurogenic = can be delayed up to 4 wkCan be delayed 4--12 wkScheduleCan be delayed 4--12 wkCan be delayed beyond 12 wkCan be delayed beyond 12 wkCarneiro et al [@bib0035]PostponeTreat as plannedTreat as plannedPostpone, suggestion under localDelayQuaedackers et al [@bib0080]As plannedPostponeRibal et al [@bib0025]Defer by 6 moFollow-up before end of 3 moMay be abandonedTreat within \<6 wkMay be abandonedTreat within \<6 wkPostponed until the end of the pandemic (at least as long as the confinement is ongoing)\
Diagnose within \<6 wk (biopsy without MRI if locally advanced or highly symptomatic)DeferredClinical harm very likely if postponed \>6 wkClinical harm very unlikely if postponed 6 moClinical harm very likely if postponed \>6 wkDefer by 6 mo\
Reimplant (\<3 mo)Summary44424342423414[^5]

4.6. Kidney transplantation, infections, trauma, low urinary tract obstruction, and andrology {#sec0070}
---------------------------------------------------------------------------------------------

All but one guideline provided recommendations for managing emergencies, which were grouped into infections, trauma/hemorrhage, benign prostatic hyperplasia and urethral stricture, transplantation, and andrology ([Table 6](#tbl0030){ref-type="table"} ). With respect to renal transplantation the EAU proposed that this be postponed for \>3 mo [@bib0025].Table 6Summary of guidelines: procedures of other subdisciplines during COVID-19 pandemic (transplantation, infections, trauma, low urinary tract obstruction, and andrology).Table 6TransplantationInfectionTraumaHemorrhageBPHUrethraAndrologyCadaveric renal txLiving donor renal txUrological abscess/wound washoutsurgical bleeding/traumaHematuria---macro (cystoscopy for)Clot retentionUrinary retention unable to place catheterBPH on self-catheterization or safe voidingUrethral stricture with imminent obstructionPenile fracturePriapismInfected prosthesis/devices (include artificial sphincter and penile implants)Acute torsionPenile prosthesis, infertility/non\--CA scrotal surgery, vasectomy/circumcision, buried penis, PeyroniesFicarra et al [@bib0010]EmergencyEmergencyEmergencyEmergencyEmergencyEmergencyEmergencyStensland et al [@bib0065]Proceed w/ immediate treatmentDelayProceed w/ immediate treatmentEmergencyEmergencyProceed w/ immediate treatmentDelayProceed w/ suprapubic tubeEmergencyProceed w/ immediate treatmentProceed w/ immediate treatmentDelayMottrie [@bib0050]UrgencyUrgencyUSANZ [@bib0015]As plannedDelay of 1--2 moTURP only if not suitable for self-catheterization or indwelling catheterAs plannedKatz et al [@bib0040]Without delayGoldman and Haber [@bib0020]EmergencyCan be delayed beyond 12 wkEmergencyEmergencyEmergencyEmergencyEmergencyCan be delayed beyond 12 wkScheduleEmergencyEmergencyEmergencyEmergencyCan be delayed beyond 12 wkAhmed et al [@bib0070]UrgentAs plannedUrgentCarneiro et al [@bib0035]EmergencyEmergencyEmergencyEmergencyEmergencyPostponePostponeEmergencyRibal et al [@bib0025]Clinical harm possible if postponed 3--4 mo but unlikely (case-by-case discussion)Clinical harm very unlikely if postponed 6 moLife-threatening situationLife-threatening situationDiagnose within \<6 wkDiagnose within \<24 hClinical harm very unlikely if postponed 6 moClinical harm very likely if postponed \>6 wkTreat within \<24 hClinical harm possible if postponed 3--4 mo but unlikelySummary24001004100004[^6]

5. Discussion {#sec0075}
=============

This systematic review aimed to synthesize available recommendations on risk/benefit ratio of delaying versus proceeding with the most commonly performed diagnostics and surgeries in urology during the COVID-19 crisis.

Redirection of resources and the prioritization of medical care aims to allow continuity of appropriate and timely assessment and management for patients with high-risk conditions, while minimizing undue risk and strain from conditions for which care can be delayed safely. In this regard, feasibility of the health care infrastructure should be determined according to the availability of health system resources, such as intensive care unit (ICU) beds, ventilators, personal protective equipment, COVID-19 tests, and health care professionals. The use of good surgical judgment can reduce the burden on health care systems across the globe. Nonoperative management should be considered whenever it is clinically appropriate for the patient. These decisions can also help limit team staffing and optimize local health care capacity to respond to the crisis.

Our systematic review of 15 clinical practice guidelines and recommendations across major urology subareas, and most routine conditions identified 761 separate recommendations for best urological practice during the COVID-19 crisis. The lack of standardization and differences among guidelines may result in skepticism about how to match resources with patient need. Some of this variation may be due to the date of publication amid the rapidly evolving case numbers and different available resources across different geographic areas.

Three of 15 (20%) guidelines have been endorsed by a specific panel or society: EAU, EAU Robotic Urology Section (ERUS), and USANZ [@bib0015], [@bib0025], [@bib0050].

In this review, we noted a paucity of recommendations on management of urological conditions with a more prolonged crisis. Only one guideline stated that recommendations should be revised if the crisis had a duration of ≥3 mo [@bib0035]. The American College of Surgeons (ACS) was referenced by the AUA web page. The ACS organized decision making into three different scenarios [@bib0055]. Phase 1 is the preparation phase for institutions and localities where COVID-19 cases are not in the rapid escalation phase, in which only a few patients are hospitalized, and beds and ICU ventilators not exhausted. In this setting, the regional leadership and surgical teams must plan to treat diseases as indicated, given that a delay in treatment could reduce the chance of being cured. Phase 2 and phase 3 are urgent settings where hospital resources are all routed to COVID-19. Pragmatically, four of the 15 papers provided the possibility of individualization of their recommendations according to different communities and hospital resources realities, using a tier system [@bib0010], [@bib0020], [@bib0025], [@bib0035]. A number of variables should be considered, such as availability of resources, whether a particular local institution is assessed as a COVID-free hospital, capacity of ICU beds and ventilators, and whether the curve has flattened.

Most of the articles reviewed are recommendations and not guidelines, primarily based on expert opinion. An exception is the EAU guidelines, which were a monumental effort proposed by a task force of 250 experts and provide evidence correlating the delay of treatment and clinical harm to survival or progression. In addition, the EAU clarifies that its guidelines are endorsed by national societies in 72 countries, providing a supporting document that urologists can use in teamwork and collaboration in their hospitals.

According to Lei et al [@bib0060], seven of 34 (20.5%) patients died after elective surgeries in Wuhan. At presentation, these patients were asymptomatic carriers and probably were in incubation phase or were infected at the hospital.

In many parts of the world, people have been asked to stay at home, and public health authorities made it mandatory to postpone elective surgery. Public health orders such as social distancing and lockdown appear to be effective at reducing the local spread of COVID-19. As the situation continues to evolve, including attempts at returning to the new normal and the threat of additional waves of infection being presented, these recommendations will require updating.

Considering uro-oncology, the pandemic has reinforced the concept of active surveillance for low-risk genitourinary tumors. Conversely, there is evidence that a delay of \>3 mo has a negative impact on the survival of patients with urothelial tumors, particularly those at high risk, and such tumors should be managed with priority. While the majority of the articles included recommendations to postpone treatment for low- and intermediary-risk PCa, the scope of recommendations regarding high-risk PCa varied. For example, Kutikov et al [@bib0030] recommended that high-risk PCa should be treated immediately, Stensland et al [@bib0065] recommended that these patients should not be operated and they should be referred to radiotherapy, and Ribal et al [@bib0025] recommended that surgery can be postponed up to 3 mo or even after the COVID-19 situation has settled.

It is important to note that patients with obstructing and infected stones should be managed, preferably by immediate decompression. In patients who have risk factors, such as pre-existing indwelling ureteral stent, symptomatic, recurrent emergency visits, solitary kidney, and bilateral ureteral calculi, close monitoring for clinical progression is warranted by telehealth, with a low threshold for additional evaluation.

Most articles point toward taking precautions to avoid contamination in the operating room. The safety of the resterilization process of endourological materials is a concern. It is highly recommended to clean surfaces with appropriate disinfectants with proven activity against enveloped viruses (hypochlorite), as 0.02% chlorhexidine digluconate can be less effective [@bib0025]. Numerous uncertainties remain in laparoscopic/robotic surgeries. It is a general recommendation to avoid generating aerosols through manipulation of the trocars and pneumoperitoneum. Concerns have also been raised about the use of electrocautery and positive pressurization rooms.

In normal times, to proceed as planned to perform a cadaveric kidney transplantation is the rule. However, special attention is needed in emergency situations such as the COVID-19 pandemic. Proponents of postponement argue that renal transplantation is highly complex and may require intensive support from a multidisciplinary team, and resources directed to combat COVID-19 might be compromised.

The timing of ambulatory cystoscopy for the diagnosis of macroscopic hematuria was an area of disagreement. Although most authors recommend proceeding with investigation of macrohematuria, two guidelines (USANZ and EAU) suggest a delay between 1 and 2 mo.

Management of emergencies (eg, ischemic testicular torsion, low-flow priapism, clot retention, and trauma) should not be delayed.

There are several limitations in our systematic review. Although these guidelines reflect an impressive effort to quickly provide guidance to urologists during a rapidly evolving emergency, the methodological quality of most guidelines was considered to be low to moderate. The level of evidence did not differ much between guidelines, and all of them were based on expert opinions. No grading of recommendations was reported. Indeed, this review highlights the need for high-quality guidelines that could be referenced in the case of future pandemics or other major emergencies. In this review, we attempted to classify recommendations in a similar fashion to Goldman and Haber's [@bib0020] priority tiers.

6. Conclusions {#sec0080}
==============

Multiple published recommendations exist to guide urology teams during the COVID-19 crisis. Recommendations support the use of active surveillance in lower-risk tumors (low-risk PCa, low-grade bladder cancer, and small renal masses), as well as considering omission of systemic therapies (neoadjuvant or adjuvant treatments) or cytoreductive nephrectomy in some advanced cases. Moreover, there was consensus to propose medical expulsive therapy for uncomplicated ureteral stones, but that infection and/or obstruction of the kidneys with a real risk of urosepsis or functional sequelae must be treated accordingly. Intravesical clots in active hematuria, infected implants, or postoperative hemorrhagic and ischemic complications are considered urological emergencies and must be treated immediately even at a time of pressure to the local health system.
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The following are Supplementary data to this article:

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.euf.2020.05.020>.

[^1]: BPH = benign prostatic hyperplasia; COVID-19 = coronavirus disease 2019; EAU = European Association of Urology; USANZ = Urological Society of Australia and New Zealand.

[^2]: ADT = androgen deprivation therapy; CA = cancer; chemo = chemotherapy; CIS = carcinoma in situ; COVID-19 = coronavirus disease 2019; EBRT = external beam radiation therapy; GCT = germ cell tumor; NSGCT = nonseminomatous GCT; RPLND = retroperitoneal lymph node dissection; SRM = small renal mass; TKI = tyrosine kinase inhibitor; U = urothelial, USANZ = Urological Society of Australia and New Zealand; VEGFR = vascular endothelial growth factor receptor; w/ = with.

[^3]: ED = emergency department; NSAID = nonsteriodal anti-inflammatory drug; PCN = percutaneous nephrostomy; USANZ = Urological Society of Australia and New Zealand.

[^4]: COVID-19 = coronavirus disease 2019; OR = operating room; PPE = personal protective equipment.

[^5]: BCG = bacillus Calmette-Guerin; CA = cancer; cysto = cystoscopy; COVID-19 = coronavirus disease 2019; MRI = magnetic resonance imaging; PCa = prostate cancer; PIRADS = Prostate Imaging Reporting and Data System; PSA = prostate-specific antigen; tx = transplant, USANZ = Urological Society of Australia and New Zealand; w/ = with.

[^6]: BPH = benign prostatic hyperplasia; CA = cancer; COVID-19 = coronavirus disease 2019; TURP = transurethral resection of the prostate; tx = transplant; USANZ = Urological Society of Australia and New Zealand; w/ = with.
